Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM

ASH 2024

7 - 10 Dec 2024

Published: 17 Dec 2024

Views: 1

Rating:

Save

Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA

Dr Peter Abdelmessieh speaks to ecancer about a study presented at ASH 2024 which analysed dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for multiple myeloma (MM).

He explains that this was a retrospective study which looked at patients receiving dexamethasone-enhanced pre-medication with the intention of reducing grade 3 and 4 hypersensitivity injection site reactions.

Dr Abdelmessieh reports that the dexamethasone-enhanced protocol decreased grade 2 reactions and saw zero grade 3 reactions.

Related Videos

Demographics, characteristics, survival and outcomes in older, untreated, AML...

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

More effective treatment options required for patients with MM post...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

More effective treatment options required for patients with MM post lenalidomide exposure ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

Manageable safety profile with early efficacy of Tec-DR in NDMM

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer